(Q38822258)

English

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 21 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Karen Basen-Engquist

14

object named as

Karen Basen-Engquist

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

Keiichi Fujiwara

8

object named as

Keiichi Fujiwara

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

author name string

Robert L Coleman

1

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Mark F Brady

2

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Thomas J Herzog

3

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Paul Sabbatini

4

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Deborah K Armstrong

5

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Joan L Walker

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Byoung-Gie Kim

7

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Krishnansu S Tewari

9

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

David M O'Malley

10

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Susan A Davidson

11

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Stephen C Rubin

12

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Paul DiSilvestro

13

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Helen Huang

15

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

John K Chan

16

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Nick M Spirtos

17

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Raheela Ashfaq

18

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Robert S Mannel

19

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

publication date

21 April 2017

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

18

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

779-791

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Emerging therapies: angiogenesis inhibitors for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Incorporation of pazopanib in maintenance therapy of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Latest research and treatment of advanced-stage epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Changing frequency of interim analysis in sequential monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

17 June 2018

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Whole-genome characterization of chemoresistant ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5715461

22 August 2018

State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930279-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30279-6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5715461

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38822258&oldid=1788775464"